Pembrolizumab Secures FDA Approval in Stomach Cancer

The FDA has granted accelerated approval to the immunotherapy drug pembrolizumab (Keytruda®) for use in patients with advanced gastric (stomach) cancer that is PD-L1 positive.

Cancer Currents: An NCI Cancer Research Blog